Abstract:Abstract We report here a novel, high analytical sensitivity multiplexed-qPCR assay for monitoring human and mouse-specific circulating cell-free DNA (cfDNA) using only 15 microliters of blood harvested from patient-derived xenograft (PDX) mice. PDX tumors maintained in murine models are commonly employed to study the biology and drug sensitivity of patient tumors. Our multiplexed qPCR assay incorporates both human and mouse multi-copy PCR amplifications targets in a single qPCR reaction. The multiplex also includes an internal synthetic DNA positive control to monitor accuracy of PCR amplification. All three targets are quantitated by monitoring three fluorophores in a single qPCR reaction. In PDX mice, the implanted human tumor sheds DNA as circulating tumor DNA (human ctDNA). Select metastatic tumors also shed human circulating tumor cells (CTCs) into the mouse’s blood that also can be detected with our assay. Our qPCR assay utilizes an Alu retrotransposon sequence, present at thousands of copies per human genome, to detect and quantitate human ctDNA, and a mouse specific multi-copy target to detect mouse cfDNA in plasma harvested from PDX mice. These high copy, repetitive elements are ideally suited for qPCR targets to quantitate circulating-tumor DNA, which is predominately in low abundance. The low detection limits of the assay (below 1pg/µL of human DNA extracted from mouse plasma) allows for longitudinal studies of mice, as the volume of blood required is minimal (as low as 15 µL) and can be repeatedly collected from live mice without the need for a terminal bleed. With the assay quantitating both human ctDNA and mouse cfDNA, normalization of the amount of tumor DNA can be calculated, allowing for more reliable tracking of the tumor growth in the mouse model. Furthermore, CTC DNA had higher measurable concentrations in the peripheral blood of both invasive TNBC PDX models compared to cfDNA concentrations. We have tested this assay successfully in mice that contain various tumor burdens (CRC, prostrate, SCLC, and TNBC). Data will be presented to show the relative amounts of human DNA present in these mice. The assay also accurately predicted the success or failure of the initial tumor engraftment of a patient tumor in a mouse—this can be used to reduce cost by eliminating unsuccessful grafts, without waiting for months to observe if the tumor grew or not. This innovative assay provides a relatively quick, economic, and easy method to monitor ongoing response to therapy. Citation Format: Sudhir K. Sinha, Hiromi Brown, Andrew Loftus, Margarite D. Matossian, Bridgette M. Collins-Burow, Matthew E. Burow. Development of a qPCR cfDNA analysis method for the assessment of tumor burden and metastatic status in live PDX mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1077.

Circulating Tumor DNA Measurement Provides Reliable Mutation Detection in Mice with Human Lung Cancer Xenografts

Quantification Of Mutant Alleles In Circulating Tumor Dna Can Predict Survival In Lung Cancer

Abstract 1077: Development of a qPCR cfDNA analysis method for the assessment of tumor burden and metastatic status in live PDX mice

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Circulating Tumor DNA Identified by Targeted Sequencing in Advanced-Stage Non-Small Cell Lung Cancer Patients.

Characterization of Cell Free Plasma Methyl-DNA From Xenografted Tumors to Guide the Selection of Diagnostic Markers for Early-Stage Cancers

Detection Of Circulating Tumor Dna In Patients With Advanced Non-Small Cell Lung Cancer

Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next‐Generation Sequencing With Insufficient Tumor Samples

Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA)

Establishment of a Digital PCR Platform for Detection of EGFR T790M Mutation in Plasma Circulating DNA from NSCLC Patients

A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal model

Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers

Circulating Tumor Dna Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer

Cross-Platform Comparison Of Four Leading Technologies For Detecting Egfr Mutations In Circulating Tumor Dna From Plasma Of Patients With Non-Small Cell Lung Carcinoma

Role of Circulating Free DNA in Evaluating Clinical Tumor Burden and Predicting Survival in Chinese Metastatic Colorectal Cancer Patients

Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma